DR info

臨床試験数 : 17 / 薬物数 : 29 - (DrugBank : 9) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 101

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
   Imperial College London
      2012   Phase 4   EUCTR2012-003136-23-GB   United Kingdom;
Cultivated oral mucosal epithelial sheet transplantation
   Seoul National University Hospital
      2014   Phase 1/Phase 2   NCT02149732   Korea, Republic of;
Cyclosporine 5 mg/kg bid days 0-14
   Vanderbilt University Medical Center
      2022   Phase 3   NCT02987257   United States;
Etanercept
   Abe Riichirou
      2021   Phase 2   JPRN-jRCTs031210325   Japan;
Etanercept 50 mg sc day 0 and day 3
   Vanderbilt University Medical Center
      2022   Phase 3   NCT02987257   United States;
Harmonized supportive care
   Vanderbilt University Medical Center
      2022   Phase 3   NCT02987257   United States;
Infliximab
   Massachusetts Eye and Ear Infirmary
      2010   Phase 1/Phase 2   NCT01256489   United States;
Intravenous immunoglobulin
   Nihon Pharmaceutical Co., Ltd
      2012   Phase 3   NCT01696500   Japan;
Lamotrigine - generic product
   Imperial College London
      2012   Phase 4   EUCTR2012-003136-23-GB   United Kingdom;
Methylprednisolone
   Morita Eishin
      2017   Phase 2   JPRN-jRCTs061180044   Germany;Japan;Taiwan;
Palifermin
   Brett King
      2010   Phase 1/Phase 2   NCT02037347   United States;
Prednisolone
   Morita Eishin
      2017   Phase 2   JPRN-jRCTs061180044   Germany;Japan;Taiwan;
Riboflavin
   Joseph B. Ciolino, MD
      2012   Phase 1/Phase 2   NCT01582880   United States;
Site specific standard of care comparison
   Massachusetts General Hospital
      2021   -   NCT03585946   -
Topical infliximab
   James Chodosh, MD, MPH
      2014   Phase 1/Phase 2   NCT02126020   Canada;United States;
cyclosporin eye drop
   Mahidol University
      2007   Phase 4   NCT01488396   Thailand;